Envarsus identity
The active ingredient recorded for this profile is Tacrolimus. Confirm the prescribed brand or ingredient before comparing packages.
Specialty Care medication reference
Envarsus (Tacrolimus) has 11 European package references in this catalog. The listed range runs from 4 mg prolonged-release tablets · 90 tablets at €2,607.96 to 4 mg prolonged-release tablets · 90 tablets at €2,907.64. No source-supported U.S. cash comparison is published for this profile; the European references should be reviewed package by package. Figures are informational, not a quote or supply guarantee.
Reference profile
The listed range runs from 4 mg prolonged-release tablets · 90 tablets at €2,607.96 to 4 mg prolonged-release tablets · 90 tablets at €2,907.64. These figures are catalog references, not an offer to sell or a guarantee of supply. The correct product, package, destination, licensed provider and importer must be reviewed for each request.
The active ingredient recorded for this profile is Tacrolimus. Confirm the prescribed brand or ingredient before comparing packages.
The listed range runs from 4 mg prolonged-release tablets · 90 tablets at €2,607.96 to 4 mg prolonged-release tablets · 90 tablets at €2,907.64. Strength, dosage form and quantity can materially change a like-for-like comparison.
No source-supported U.S. cash comparison is published for this profile; the European references should be reviewed package by package.
Package references
European figures are dated estimated medicine cost references. U.S. cash context appears only where the catalog retains source provenance; compare the exact strength, form and quantity.
No package references match that search. Try a shorter strength, dosage form, supplier or PZN.
| Package reference | Estimated medicine cost reference | Comparable U.S. cash reference | Estimated difference | Source notes | Select |
|---|---|---|---|---|---|
| 4 mg prolonged-release tablets · 90 tablets EMRA-MED Arzneimittel GmbH · PZN 13901242 | €2,607.96 | Not listed | Case-specific comparison | Dated European EUR source record; current price and availability require review. Recorded review: European source record ↗ | Request this package |
| 4 mg prolonged-release tablets · 90 tablets 1 0 1 Carefarm GmbH · PZN 15198752 | €2,608.37 | Not listed | Case-specific comparison | Dated European EUR source record; current price and availability require review. Recorded review: European source record ↗ | Request this package |
| 4 mg prolonged-release tablets · 90 tablets Originalis B.V. · PZN 15568172 | €2,609.29 | Not listed | Case-specific comparison | Dated European EUR source record; current price and availability require review. Recorded review: European source record ↗ | Request this package |
| 4 mg prolonged-release tablets · 90 tablets ACA Müller/ADAG Pharma AG · PZN 16885704 | €2,609.58 | Not listed | Case-specific comparison | Dated European EUR source record; current price and availability require review. Recorded review: European source record ↗ | Request this package |
| 4 mg prolonged-release tablets · 90 tablets axicorp Pharma B.V. · PZN 12501285 | €2,617.10 | Not listed | Case-specific comparison | Dated European EUR source record; current price and availability require review. Recorded review: European source record ↗ | Request this package |
| 4 mg prolonged-release tablets · 90 tablets Chiesi GmbH · PZN 10410259 | €2,877.51 | Not listed | Case-specific comparison | Dated catalog record; current price and availability require review. Recorded review: | Request this package |
| 4 mg prolonged-release tablets · 90 tablets Abacus Medicine A/S · PZN 13343575 | €2,907.36 | Not listed | Case-specific comparison | Dated European EUR source record; current price and availability require review. Recorded review: European source record ↗ | Request this package |
| 4 mg prolonged-release tablets · 90 tablets Orifarm GmbH · PZN 11555853 | €2,907.40 | Not listed | Case-specific comparison | Dated European EUR source record; current price and availability require review. Recorded review: European source record ↗ | Request this package |
| 4 mg prolonged-release tablets · 90 tablets B2B Medical GmbH · PZN 19253028 | €2,907.49 | Not listed | Case-specific comparison | Dated European EUR source record; current price and availability require review. Recorded review: European source record ↗ | Request this package |
| 4 mg prolonged-release tablets · 90 tablets EurimPharm Arzneimittel GmbH · PZN 13859209 | €2,907.57 | Not listed | Case-specific comparison | Dated European EUR source record; current price and availability require review. Recorded review: European source record ↗ | Request this package |
| 4 mg prolonged-release tablets · 90 tablets kohlpharma GmbH · PZN 12739762 | €2,907.64 | Not listed | Case-specific comparison | Dated European EUR source record; current price and availability require review. Recorded review: European source record ↗ | Request this package |
Displayed amounts are dated catalog references and may not include every tax, dispensing, shipping or route-specific cost. Exact identity, availability, prescription, destination and import route require separate review. U.S. amounts are shown only for records with retained comparison provenance. US Med Access does not dispense or sell medicines and provides no medical advice. Review the pricing and data methodology before comparing packages.
How the references are preparedSources and editorial responsibility
US Med Access publishes this page as an independent reference-information provider. Package records are retained with their available source notes and review dates; missing provenance is stated rather than inferred.
Frequently asked questions
Direct answers based on the package records shown on this page. They do not replace medical, regulatory or dispensing advice.
The 11 listed European package references range from €2,607.96 – €2,907.64. The exact amount depends on strength, dosage form and pack quantity, so compare the specific package row rather than the range alone.
No source-supported U.S. cash-price comparison is published for this profile. US Med Access does not estimate a U.S. figure when the catalog lacks adequate provenance.
No. They are informational catalog references. US Med Access is an independent sourcing consultant and does not sell or dispense medicines. Current availability, route, prescription and total cost require separate review.
Select the row that matches the prescribed strength, dosage form and quantity, then include the destination and request details. A package-level review is required before any next step.
Availability and logistics
Start with the medication, package and destination. The sourcing team will assess the specific request without promising a supply, import or delivery outcome.